Kornimate/medical-research-clean huggingface dataset:
study of tranilast alone or in combination with allopurinol in subjects with hyperuricemia

Conditions: Gout; Hyperuricemia

Summary: this is a randomized, double-blind, 3-period 3-treatment crossover followed by a 2-period 2-treatment crossover, phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on allopurinol pharmacokinetics (pk) and pharmacodynamics (pd) and to evaluate the effect of allopurinol on tranilast pk and pd as measured by reduction in serum uric acid levels.


Eligibility criteria:
inclusion criteria: * male or female, aged 21 to 70 * subjects with hyperuricemia who are otherwise healthy exclusion criteria: * pregnant or nursing * known history of gout unless approved by the investigator or sponsor * clinically significant infection at screening * known sensitivity to tranilast or allopurinol

Keywords: gout hyperuricemia
association of periodontal disease and gut microbiome with coronary artery disease (produce study)

Conditions: Periodontitis; Coronary Heart Disease; Human Microbiome; Dysbiosis

Summary: the purpose of this study is to explore the relationship between periodontal disease and coronary artery disease through changes in the gut microbiome. in addition, the investigators aim to find possible periodontal pathogens that have association with cardiovascular disease.

the previous studies have reported the associations among cardiovascular disease, periodontitis, and gut microbiome dysbiosis. however, there is a lack of evidences about the axis of association from oral-gut-cardiovascular disease. the investigators hypothesized that periodontal disease might induce dysbiosis of gut microbiome and dysbiosis might have a role in cardiovascular disease (as called "oro-gut-vascular axis"). the investigators aim to prove this hypothesis through this case-control, cross-sectional study.

Eligibility criteria:
inclusion criteria: -patients aged from 19 to 80 years who underwent invasive coronary angiography for clinical necessity, with informed consent exclusion criteria: * patients with prosthetic valve * pregnancy * active malignancy * active autoimmune disease * active inflammatory bowel disease * chronic kidney disease (egfr\<30, or on dialysis) * active liver disease or liver cirrhosis * consistent use of probiotics * prior gastrointestinal surgery within 1 year
microbial study of sublingual immunotherapy spray in patients with allergic rhinitis

Conditions: Rhinitis, Allergic

Summary: the incidence of allergic rhinitis (ar) in chinese adults was reported to be as high as 24.1% and 16.8% in children. the current symptomatic treatment has the disadvantage of poor efficacy and cannot change the natural course of the disease. allergen immunotherapy (ait) is the only causative treatment approved by the who, bringing a new option to patients with allergic diseases. the quality of allergen preparations is critical to the diagnosis and treatment of the disease, emphasizing the need for standardized preparations, and ait treatment in the early stages of the disease may change the long-term progression of the disease. recent studies have reported that the microbiome of patients with different efficacy of desensitization therapy is different and may be correlated with the clinical symptoms of patients, but no prospective studies have been reported.


Eligibility criteria:
inclusion criteria: * adult patients (18-65 years). * patients with canis familiari/felis domesticus/alternaria alternata allergic rhinitis were diagnosed based on clinical history and positive dust mite sensitization tests (skin prick test and/or specific ige). * patients who visited the department of otolaryngology of the first affiliated hospital of nanjing medical university and selected sublingual spray desensitization. exclusion criteria: * patients who refused to accept specimen and questionnaire collection. * patients who had nasal diseases other than allergic rhinitis, such as nasal papilloma and nasal malignant tumor.
desogestrel (dsg) and corifollitropin(fsh-ctp) alfa for ovarian stimulation in donors

Conditions: Infertility

Summary: currently, controlled ovarian stimulation (cos) in oocyte donors is performed by daily injections of gonadotropins( recombinant fsh) plus a gnrh antagonist usually form 5th-6th stimulation day until ovulation induction with a bolus of another injection of a gonadotropin-releasing hormone (gnrh) agonist. injections of the gnrh antagonist avoid untimely luteinizing hormone (lh) surge and spontaneous ovulation prior to follicular aspiration. there is a preparation of long-acting recombinant follicle stimulating hormone (rfsh= (corifollitropin alfa (fsh-ctp), elonva®, msd), that allows that a single subcutaneous injection substitutes the first 7 days of daily gonadotropin injections. on the other hand, a contraceptive oral progesterone only( desogestrel, dsg) is available for contraception, avoiding the lh surge. it has been described the usefulness of orally administered medroxyprogesterone acetate, 10 mg to inhibit the endogenous lh surge in ivf patients during cos. in donors, by administering a single injection of fsh-ctp and oral desogestrel since the first menstruation day, the total number of injections administered is reduced and less discomfort is experienced without adverse impact on ovarian response. no description of the hormonal and ovarian response under this protocol has been published

* oral desogestrel since the first menstruation day, * a single injection of fsh-ctp on the 7th menstrual cycle day * routine monitoring of ovarian response with transvaginal ultrasound every second day until pre-ovulatory bolus of gnrh * hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of gnrh and the day after the bolus ( estradiol, fsh, progesterone, lh) * quality of life questionnaire the day after the bolus

Eligibility criteria:
inclusion criteria: * population: donors (18-35 ) from candidates of donor program * fulfilling inclusión medical and legal criteria (rd -ley de transposición de la normativa europea a la legislación española 9/2014) * who had had undergone previously convencional cos (controlled ovarian stimulation) with fsh-ctp and daily antagonist injections * given signed consent form. exclusion criteria: * previous low response to cos * previous ovarian hyperstimulation syndrome. * ovarian cysts.

Keywords: ovarian stimulation lh inhibition
methanol poisoning

Conditions: Methanol Poisoning

Summary: this study addresses methyl alcohol intoxications with profound acidosis requiring intensive care treatment. the goal is to contribute both to the improvement of diagnosis and follow-up processes and to the development of management strategies under the highlight of existing literature. this study is a single-center, retrospective, observational cohort study conducted on patients admitted to the icu between january 2022 and march 2025 with suspected or laboratory-confirmed methyl alcohol intoxication. the investigators analyzed patients' demographic characteristics, prognostic clinical and laboratory parameters, treatment approaches and outcomes

this study addresses methyl alcohol intoxications with profound acidosis requiring intensive care treatment. the objective is to contribute to the improvement of diagnostic and follow-up processes, as well as to the development of management strategies, in light of the existing literature. the study is a single-center, retrospective, observational cohort analysis conducted on patients admitted to the intensive care unit (icu) between january 2022 and march 2025 with suspected or laboratory-confirmed methyl alcohol intoxication. data collection was performed in three steps. initially, the hospital's electronic medical database was searched using the icd code t51.1 to identify relevant cases. subsequently, detailed medical records were reviewed to assess clinical progress and treatment interventions. finally, laboratory findings were obtained through the hospital's patient record system. demographic characteristics-including age and gender-reasons for icu admission, pre-existing conditions, presenting symptoms, and disease severity based on acute physiology and chronic health evaluation ii (apache ii), glasgow coma scale (gcs), sequential organ failure assessment (sofa), and simplified acute physiology score (saps) evaluated during the first 24 hours of icu stay were retrospectively analyzed. treatment interventions, including ethanol or fomepizole administration, the need for hemodialysis (intermittent hemodialysis \[ihd\] or continuous venovenous hemodialysis \[cvvhd\]), supportive therapies, icu length of stay, and clinical outcomes were also documented. laboratory evaluations included arterial blood gas analysis, anion gap, osmolality, complete blood count, glucose, urea, creatinine, electrolytes (sodium, potassium, chloride), c-reactive protein (crp), and organ function tests such as aspartate aminotransferase (ast) and alanine aminotransferase (alt). demographic data, prognostic clinical and laboratory parameters, treatment modalities, and clinical outcomes were analyzed by the investigators.

Eligibility criteria:
inclusion criteria: • clinical diagnosis of methyl alcohol intoxication. exclusion criteria: * other toxic alcohol intoxications * pregnant women

Keywords: methanol intoxication intensive care mortality
a study of tq-b3101 in subjects with relapsed or refractory anaplastic large cell lymphoma (alcl)

Conditions: Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

Summary: the objective of this study is to evaluate efficacy and safety of tq-b3101 in subjects with relapsed/refractory anaplastic large cell lymphoma (alcl) .


Eligibility criteria:
inclusion criteria: -1.female or male, 10 years and older. 2.eastern cooperative oncology group (ecog) performance status score of 0 to 2. 3.histologically or cytologically confirmed alk positive relapsed or refractory anaplastic large cell lymphoma. 4.at least one measurable lesion. 5.life expectancy ≥ 3 months. 6.adequate organ system function. 7.understood and signed an informed consent form. exclusion criteria: * 1.primary cutaneous anaplastic large cell lymphoma. 2.other malignancies occurred within 5 years, with exception of cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors. 3.has received alk inhibitor. 4.has received an allogeneic stem cell transplant. 5.has received autologous stem cell transplant within 12 weeks before the first administration. 6.has received other anti-tumor medications within 4 weeks of the first administration. 7.has received major surgery within 4 weeks before the first administration. 8.has received any curative radiotherapy or minor surgery within 2 weeks before the first administration. 9.has received palliative radiation therapy within 2 days before the first administration. 10.has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1. 11.has uncontrollable congestive heart failure. 12.according to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
ngly1 deficiency: a prospective natural history study

Conditions: Genetic Syndrome

Summary: ngly1 deficiency is a rare genetic disorder that is characterized by: global developmental delay and/or intellectual disability, hypo- or alacrima, transient elevation of transaminases, and a hyperkinetic movement disorder. significant phenotypic variability has been observed in the small number of affected individuals described in the medical literature. the purpose of this study is to describe the natural history of ngly1 deficiency in a prospective, detailed, and highly uniform manner. study participants will be closely monitored over the course of five years in order to: * understand the clinical spectrum and progression of ngly1 deficiency using standardized clinical and neurodevelopmental assessments * identify clinical and biomarker endpoints for use in therapeutic trials, and * identify genotype-phenotype correlations close clinical follow-up will allow for generation of a rich dataset and detailed understanding of the natural history of ngly1 deficiency.


Eligibility criteria:
inclusion criteria: * parent(s)/legal representative and/or participant must be willing and able to give informed consent/assent for participation in the study * males or females of any age * suspected or confirmed diagnosis of ngly1 deficiency with genetic variants in both ngly1 alleles and consistent clinical characteristics * participant and caregiver must be willing to provide clinical data, participate in standardized assessments, and provide biological samples (if living in the united states) * willingness to travel to palo alto, ca is favored, but not required exclusion criteria: * the presence of a second, confirmed disorder, genetic or otherwise, affecting neurodevelopment or with other overlapping symptoms of ngly1 deficiency

Keywords: ngly1 deficiency
access to care and adherence tuberculosis (tb) survey

Conditions: Tuberculosis

Summary: prompt access to care and treatment adherence are the hearth of tuberculosis control. this is a multicentre observational prospective study aimed at studying the factors associated with delayed access to care and low adherence to anti-tuberculosis treatment. hetero- and self-administered questionnaires will be used at enrollment to assess clinical presentation and time and modalities of the diagnosis. treatment adherence will be assessed during the follow-up with self administered questionnaires.


Eligibility criteria:
inclusion criteria: * \>= 18 yrs of age * recent new tb diagnosis * tuberculosis treatment prescribed * ability to sign the informed consent
evaluation of ffr, wss, and tpf using ccta

Conditions: To Assess the Feasibility of CT-derived FFR, WSS and TPF on Coronary Atherosclerotic Plaque

Summary: to assess the feasibility of ct-derived computed fractional flow reserve (ffrct), wall shear stress and total plaque force on coronary atherosclerotic plaque and to collect the preliminary data to apply those parameters for the prediction of clinical outcomes in patients with coronary artery stenosis.


Eligibility criteria:
inclusion criteria: * consecutive patients with available ccta within 3 months of invasive angiography and invasive imaging methods (ivus or oct) exclusion criteria: * poor ct images (unable to reconstruct 3 dimensional coronary artery model)
based on the data from the zhejiang emergency center, explore the independent and interactive effects of the association between meteorological factors and air pollution and the number of emergency personnel, identify the relevant vulnerable population characteristics, sensitive disease types

Conditions: Fig. Impetuous

Summary: based on the health data from zhejiang emergency command center, combined with meteorological, air pollution, land use and socio-economic data of zhejiang province, distributional lag nonlinear models, grouped weighted quantile and regression and bayesian spatial models were used to explore the independent and interactive effects of the association between meteorological factors and air pollution and the number of first-aiders, to identify the related characteristics of the vulnerable populations, the types of sensitive diseases and the high-risk areas, and to elucidate the driving factors of the association between meteorological factors and air pollution and the number of first-aiders. it also clarifies the drivers of the association between meteorological factors and air pollution and the number of emergencies, so as to provide a reference for the government to take targeted measures to reduce the burden of related healthcare services.


Eligibility criteria:
inclusion criteria: -emergency data of zhejiang emergency command center in the past 5 years exclusion criteria: * prehospital emergency information from non-zhejiang province domains * emergency calls due to labor and delivery.
self-expanding nitinol stent versus balloon angioplasty alone for the below the knee arteries(sens-btk)

Conditions: Critical Limb Ischemia; Infrapopliteal Arterial Occlusive Disease

Summary: the objectives of this study are to compare directly conventional balloon angioplasty alone versus. balloon angioplasty with routine stenting - that is, to determine whether angioplasty with self-expanding stent is superior to conventional balloon angioplasty - in the infrapopliteal arterial occlusive lesions of critical limb ischemia patients by collecting and analyzing the cases of each patient group in a prospective multicenter randomized clinical trial, and to clarify main factors affecting mid- and long-term clinical effects of angioplasty with self-expanding stent in the infrapopliteal arteries. hypothesis: balloon pta followed by routine stenting with self-expanding nitinol stent in critical limb ischemia patients with infrapopliteal arterial occlusive lesions is superior to conventional pta in the aspect of vascular restenosis rate.


Eligibility criteria:
inclusion criteria: * symptomatic critical limb ischemia (rutherford 4 - 6) * patients with signed informed consent * target lesion length \< 8 cm by angiographic estimation * stenosis of \>50% or occlusive atherosclerotic lesion of the ipsilateral infrapopliteal artery * reference vessel diameter should be 2.0-4.5 mm exclusion criteria: * patient has a known allergy to heparin, aspirin, or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies * patient takes warfarin * patient has a history of previous life-threatening contrast media reaction * patient is currently enrolled in another investigational device or drug trial * patient is currently breast-feeding, is pregnant, or intends to become pregnant * patient is mentally ill or retarded * acute critical limb ischemia * major bleeding history within prior 2 months * severe hepatic dysfunction (\> 3 times normal reference values) * significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis * life expectancy \<1 year due to comorbidity * reference segment diameter is not suitable for available stent design * previously implanted stent(s) or pta at the same lesion site * inflow-limiting arterial lesions left untreated
online peer networked collaborative learning for managing depressive symptoms

Conditions: Depression

Summary: the goal of this field trial is to tailor and test a web-based intervention in adults 65 years of age or older. two versions of the web-based intervention have been created and will be tested--one with an online social network and one without an online social network. the purpose of this study is to: pilot a novel intervention, examine methods to improve adherence to web-based interventions (e.g., peer network); collect data on feasibility, acceptability, and efficacy of an web-based intervention for late life depression; and ultimately, to overcome the numerous barriers to treating depression in later life.


Eligibility criteria:
inclusion criteria: * has elevated depressive symptoms * has a telephone, e-mail account, computer, and broadband access to the internet. * has basic internet skills and is able to access the internet independently * is able to speak and read english. * is at least 65 years of age. * is able to give informed consent. exclusion criteria: * has hearing or voice impairment that would prevent participation in psychotherapy * has visual impairment that would prevent completion of assessment materials. * is diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current substance abuse, or other diagnosis for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous. * is currently receiving individual psychotherapy or planning to receive psychotherapy during the 8-week treatment phase of the study * is planning to be out of town or unavailable for an extended period of time during the study without access to the internet * exhibits severe suicidality, including ideation, plan, and intent. * has initiated treatment with an antidepressant in past 14 days. once patients have been on a stable dose for 14 days and do not have an appointment with a physician or psychiatrist to change this dose, the patient will be eligible based on this criterion.

Keywords: depression web-based intervention aging geriatrics social network older adults
impaired immunity in patients with cancer: influence of cancer stage, chemotherapy, and cytomegalovirus infection

Conditions: Neoplasms

Summary: according to a survey from department of health in 2004, cancer has been the leading cause of death in the taiwan area. in 2004, people died of cancer, accounting for 27.2 percent of all deaths. the major reason of the superior grade is that cancer has the ability to escape the surveillance of immune system. it is also a main issue to address in medical research. dendritic cells (dcs), the most potent apc, are located at sites of pathogen entry, acquire antigens from pathogens or pathogen-infected cells, and process these antigens for both class i and class ii presentation. upon antigen encounter, they termed immature dcs, undergo a maturation process, they are capable to present captured antigens to t cells. this maturation step allows dc migration to trigger adaptive immune responses. these features make dcs very good candidates for therapy against various pathological conditions including malignancies. therefore, two concepts in this project will be concerned: one is enhancement of t cell immunity and the other is improvement of the efficiency of dc-tumor fusion. the strategy of enhance t cell is using well-known cytokines, such as il2, and il7 to expand the tumor-specific cd4 and cd8 t cells before dc-vaccine treatment. in the past, scientists utilized polyethyleneglycol to fuse cancer cells and dendritic cells. however, the results were devastating. two new approaches of the dc vaccine will be applied to this study: dc-tumor fusion and dc phagocytosed apoptosed tumor cells. whole tumor cells will be fused with dcs by combining hypotonic buffer and electrical-based fusion protocols. the safety of hybrid cell vaccination has been shown in clinical trials with some encouraging anti-tumour effects. however, data are as yet insufficient to assess a clear therapeutic benefit. hopefully, the combination of two strategies will improve the efficiency of dc vaccine and boost survival of cancer patients. as we have gained a clearer understanding of the cellular and molecular events that modulate antigen presentation and t cell activation in vivo, new strategies have emerged, allowing the development of more potent second generation dc vaccines.


Eligibility criteria:
inclusion criteria: * for observational study: health volunteers and cancer patients * for dc vaccine: patients with solid tumor exclusion criteria: * leukemia

Keywords: immunologic surveillance vaccination immunotherapy dendritic cells